Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Caterpillar fungus could hold key to new osteoarthritis treatments
The caterpillar fungus Cordyceps militaris could hold the key to new treatments for osteoarthritis.

Active compound can reduce pain and halt disease progression

A fungus that infects caterpillars, Cordyceps militaris, could hold the key to new treatments for osteoarthritis, according to new research.

The study, published in the journal Scientific Reports, suggests that an active compound in the fungus, cordycepin, could reduce pain and halt disease progression.

Scientists say it works by blocking inflammation in an entirely different way to any other pain killer - by repressing a process called polyadenylation - and could be used to help patients for which other treatments have failed.

The study was led by the University of Nottingham and funded by the charity ‘Versus Arthritis’.

“We hope that cordycepin will prove to be the founder of a new class of pain killer,” explained Dr Cornelia De Moor from the University of Nottingham’s School of Pharmacy. “There is a long way to go before a cordycepin-derived medicine reaches patients, but our work is very promising, we are very excited about the prospects.”

Previous work by the University of Nottingham found that cordycepin had anti-inflammatory effects in both cartilage and bone. In this study, researchers administered the compound to rats and mice with osteoarthritis and found that it both reduced pain behaviour and structural damage.

Interestingly, researchers found that cordycepin blocked the inflammation by affecting the last stage of making a messenger RNA, Polyadenylation.

Current treatment options for osteoarthritis are limited to lifestyle changes and reducing pain with non-steroidal anti-inflammatories or opioids. But these have limited efficacy and come with unpleasant side effects.

The team hope that the results from this new research will provide a more effective treatment for osteoarthritis that is less toxic and will, therefore, have fewer side effects for patients.

Dr Stephen Simpson from Versus Arthritis said: “Although in its early stages, the study has great potential suffering pain of musculoskeletal conditions and demonstrated the high value and impact of novel discovery-led research on understanding and treating diseases.”

Image (C) Jose Ramon Pato, Coruña, España.

Become a member or log in to add this story to your CPD history

Building Great Workplaces webinars return

News Story 1
 BVA has announced a new series of its Building Great Workplaces lunchtime webinars.

Launching from 16 July, the sessions will explore patient safety, motivation, client communication and more.

Its first webinar, exploring neurodiversity in the workplace, will take place at 1pm on Thursday, 16 July. It will feature guest speakers from The Vet Project, a group which supports neurodiversity in veterinary environments.

The following three webinars take place in September, October and November.

Booking is open on the BVA website 

Click here for more...
News Shorts
New form for online veterinary medicines retailers

The Veterinary Medicines Directorate (VMD) has produced a new online form for retailers wishing to sell veterinary medicines on the internet.

The form replace the previous Word version and is part of the VMD's ongoing commitment to digitise its processes. Anyone retailing prescription medicines online, including POM-V, POM-VPS and NFA-VPS categories, is lawfully required to register with the VMD before trading.

The change only applies to new applicants. Retailers already listed on the VMD's Register of Online Retailers or registered under the Accredited Internet Retailer Scheme (AIRS) do not need to do anything.